المؤلفون: Tacconi EMC, Tuthill M, Protheroe A

المصدر: OncoTargets and Therapy, Vol Volume 13, Pp 12301-12316 (2020)

مصطلحات موضوعية: renal cell carcinoma, adjuvant therapy, tyrosine kinase inhibitors, immune checkpoint inhibitors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/review-of-adjuvant-therapies-in-renal-cell-carcinoma-evidence-to-date-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930

URL الوصول: https://doaj.org/article/80a339ae6196488fb65260e37980666e

المؤلفون: Landeiro F; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Harris C; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Groves D; Clinical Trials Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., O'Neill S; Strathesk Medical Practice, NHS Lothian, Edinburgh, UK., Jandu KS; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Tacconi EMC; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Field S; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Patel N; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Göpfert A; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Hagson H; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Leal J; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Luengo-Fernández R; National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: ramon.luengo-fernandez@dph.ox.ac.uk.

المصدر: The lancet. Healthy longevity [Lancet Healthy Longev] 2024 Aug; Vol. 5 (8), pp. e514-e523. Date of Electronic Publication: 2024 Jul 25.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101773309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-7568 (Electronic) Linking ISSN: 26667568 NLM ISO Abbreviation: Lancet Healthy Longev Subsets: MEDLINE

مواضيع طبية MeSH: Dementia*/economics , Dementia*/epidemiology , Neoplasms*/economics , Neoplasms*/epidemiology , Neoplasms*/mortality , Cost of Illness* , Coronary Disease*/economics , Coronary Disease*/epidemiology , Coronary Disease*/mortality , Stroke*/economics , Stroke*/epidemiology , Stroke*/mortality, Humans ; England/epidemiology ; Female ; Male ; Aged ; Middle Aged ; Cohort Studies ; Health Care Costs/statistics & numerical data ; Health Care Costs/trends ; Adult ; Longitudinal Studies ; Aged, 80 and over

المؤلفون: Dagg RA; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Zonderland G; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK.; Center for Chromosome Stability, Institute for Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Lombardi EP; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Rossetti GG; Department of Molecular Biology, University of Geneva, Geneva, Switzerland., Groelly FJ; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Barroso S; Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad de Sevilla-Consejo Superior de Investigaciones Científicas-Universidad Pablo de Olavide, Seville, Spain., Tacconi EMC; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK., Wright B; Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Lockstone H; Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK., Aguilera A; Centro Andaluz de Biología Molecular y Medicina Regenerativa (CABIMER), Universidad de Sevilla-Consejo Superior de Investigaciones Científicas-Universidad Pablo de Olavide, Seville, Spain., Halazonetis TD; Department of Molecular Biology, University of Geneva, Geneva, Switzerland., Tarsounas M; Genome Stability and Tumourigenesis Group, MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, UK. madalena.tarsounas@oncology.ox.ac.uk.

المصدر: Nature communications [Nat Commun] 2021 Aug 13; Vol. 12 (1), pp. 4919. Date of Electronic Publication: 2021 Aug 13.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

مواضيع طبية MeSH: BRCA1 Protein/*genetics , BRCA2 Protein/*genetics , Oncogenes/*genetics , Transcription, Genetic/*genetics , beta Catenin/*genetics, BRCA1 Protein/deficiency ; BRCA2 Protein/deficiency ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Cell Line, Tumor ; Cell Proliferation/genetics ; Cell Survival/genetics ; Cells, Cultured ; Cyclin-Dependent Kinase Inhibitor p21/genetics ; Cyclin-Dependent Kinase Inhibitor p21/metabolism ; DNA Damage ; Female ; Gene Expression Profiling/methods ; HeLa Cells ; Humans ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/metabolism ; RNA-Seq/methods ; beta Catenin/metabolism

المؤلفون: McGowan DR; Department of Oncology, University of Oxford, Oxford, United Kingdom; Radiation Physics and Protection, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Skwarski M; Department of Oncology, University of Oxford, Oxford, United Kingdom; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Bradley KM; Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Campo L; Department of Oncology, University of Oxford, Oxford, United Kingdom., Fenwick JD; Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Gleeson FV; Department of Oncology, University of Oxford, Oxford, United Kingdom; Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Green M; Department of Oncology, University of Oxford, Oxford, United Kingdom., Horne A; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Maughan TS; Department of Oncology, University of Oxford, Oxford, United Kingdom., McCole MG; Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Mohammed S; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom., Muschel RJ; Department of Oncology, University of Oxford, Oxford, United Kingdom., Ng SM; Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, United Kingdom., Panakis N; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Prevo R; Department of Oncology, University of Oxford, Oxford, United Kingdom., Strauss VY; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom., Stuart R; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Tacconi EMC; Department of Oncology, University of Oxford, Oxford, United Kingdom., Vallis KA; Department of Oncology, University of Oxford, Oxford, United Kingdom; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., McKenna WG; Department of Oncology, University of Oxford, Oxford, United Kingdom., Macpherson RE; Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Higgins GS; Department of Oncology, University of Oxford, Oxford, United Kingdom; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. Electronic address: geoffrey.higgins@oncology.ox.ac.uk.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 May; Vol. 113, pp. 87-95. Date of Electronic Publication: 2019 Apr 13.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Tumor Hypoxia*, Adenocarcinoma of Lung/*therapy , Aminopyridines/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*therapy , Carcinoma, Squamous Cell/*therapy , Lung Neoplasms/*therapy , Morpholines/*therapeutic use , Phosphoinositide-3 Kinase Inhibitors/*therapeutic use , Radiation-Sensitizing Agents/*therapeutic use, Adenocarcinoma of Lung/diagnostic imaging ; Adenocarcinoma of Lung/metabolism ; Aged ; Anorexia/chemically induced ; Carcinoma, Non-Small-Cell Lung/diagnostic imaging ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Squamous Cell/diagnostic imaging ; Carcinoma, Squamous Cell/metabolism ; Chemoradiotherapy ; Fatigue/chemically induced ; Female ; Humans ; Lung Neoplasms/diagnostic imaging ; Lung Neoplasms/metabolism ; Male ; Maximum Tolerated Dose ; Middle Aged ; Misonidazole/analogs & derivatives ; Nausea/chemically induced ; Positron Emission Tomography Computed Tomography ; Radiotherapy

المؤلفون: Zimmer J; Genome Stability and Tumourigenesis Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Tacconi EMC; Genome Stability and Tumourigenesis Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Folio C; Genome Stability and Tumourigenesis Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Badie S; Genome Stability and Tumourigenesis Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Porru M; Area of Translational Research, Regina Elena National Cancer Institute, 00144 Rome, Italy., Klare K; Genome Stability and Tumourigenesis Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Tumiati M; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, P.O. Box 20, FIN-00014 Helsinki, Finland., Markkanen E; Biochemistry and Regulation of DNA Repair Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Halder S; DNA Damage and Repair Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Ryan A; Lung Cancer Translational Science Research Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Jackson SP; The Gurdon Institute, CRUK Laboratories, University of Cambridge, Tennis Court Road, Cambridge CB2 1QN, UK; The Sanger Institute, Hinxton, Cambridge CB10 1SA, UK., Ramadan K; DNA Damage and Repair Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK., Kuznetsov SG; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, P.O. Box 20, FIN-00014 Helsinki, Finland., Biroccio A; Area of Translational Research, Regina Elena National Cancer Institute, 00144 Rome, Italy., Sale JE; Medical Research Council Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK., Tarsounas M; Genome Stability and Tumourigenesis Group, CRUK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK. Electronic address: madalena.tarsounas@oncology.ox.ac.uk.

المصدر: Molecular cell [Mol Cell] 2016 Feb 04; Vol. 61 (3), pp. 449-460. Date of Electronic Publication: 2015 Dec 31.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 9802571 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4164 (Electronic) Linking ISSN: 10972765 NLM ISO Abbreviation: Mol Cell Subsets: MEDLINE

مواضيع طبية MeSH: Aminoquinolines/*pharmacology , Antineoplastic Agents/*pharmacology , BRCA1 Protein/*deficiency , BRCA2 Protein/*deficiency , Biomarkers, Tumor/*deficiency , G-Quadruplexes/*drug effects , Neoplasms/*drug therapy , Picolinic Acids/*pharmacology, Animals ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Biomarkers, Tumor/genetics ; Cell Proliferation/drug effects ; DNA Breaks, Double-Stranded ; Dose-Response Relationship, Drug ; Drug Resistance, Neoplasm ; G2 Phase Cell Cycle Checkpoints/drug effects ; HEK293 Cells ; Humans ; Intracellular Signaling Peptides and Proteins/genetics ; Intracellular Signaling Peptides and Proteins/metabolism ; Mad2 Proteins/genetics ; Mad2 Proteins/metabolism ; Male ; Mice, Nude ; Molecular Targeted Therapy ; Neoplasms/genetics ; Neoplasms/metabolism ; Neoplasms/pathology ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; RNA Interference ; Telomere/drug effects ; Telomere/genetics ; Telomere/metabolism ; Time Factors ; Transfection ; Tumor Burden/drug effects ; Tumor Suppressor p53-Binding Protein 1 ; Xenograft Model Antitumor Assays